Associated Papers
Ribonuclease RNase Z is an evolutionarily conserved deAMPylase.
Mukherjee M et al.
Proceedings of the National Academy of Sciences of the United States of America, 2025
Structural basis of 3'-tRNA maturation by the human mitochondrial RNase Z complex.
Valentín Gesé G et al.
The Embo Journal, 2024
Structural insights into human ELAC2 as a tRNA 3' processing enzyme.
Xue C et al.
Nucleic Acids Research, 2024
Why Don't More Mitochondrial Diseases Exhibit Cardiomyopathy?
Singh N et al.
Journal of Cardiovascular Development and Disease, 2023
Mutations in ELAC2 associated with hypertrophic cardiomyopathy impair mitochondrial tRNA 3'-end processing.
Saoura M et al.
Human Mutation, 2019
The molecular biology of prostate cancer: current understanding and clinical implications.
Gandhi J et al.
Prostate Cancer and Prostatic Diseases, 2018
Exome Pool-Seq in neurodevelopmental disorders.
Popp B et al.
European Journal of Human Genetics : Ejhg, 2017
The crystal structure of Trz1, the long form RNase Z from yeast.
Ma M et al.
Nucleic Acids Research, 2017
iFish: predicting the pathogenicity of human nonsynonymous variants using gene-specific/family-specific attributes and classifiers.
Wang M et al.
Scientific Reports, 2016
The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its product.
Minagawa A et al.
Cancer Letters, 2005
Characterization of TRZ1, a yeast homolog of the human candidate prostate cancer susceptibility gene ELAC2 encoding tRNase Z.
Chen Y et al.
Bmc Molecular Biology, 2005
Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer.
Camp NJ et al.
Genetic Epidemiology, 2005
Prostate cancer susceptibility genes: lessons learned and challenges posed.
Simard J et al.
Endocrine-related Cancer, 2003
A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease.
Takaku H et al.
Nucleic Acids Research, 2003
The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex.
Korver W et al.
International Journal of Cancer, 2003
Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer.
Camp NJ et al.
American Journal of Human Genetics, 2002
Perspective: prostate cancer susceptibility genes.
Simard J et al.
Endocrinology, 2002
Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series.
Fujiwara H et al.
Journal of Human Genetics, 2002
ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.
Rökman A et al.
Cancer Research, 2001
A candidate prostate cancer susceptibility gene at chromosome 17p.
Tavtigian SV et al.
Nature Genetics, 2001